MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/po-24-00790

Медицинская библиотека · JCO precision oncology · 2025

Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non-Small Cell Lung Cancer.

Chiaruttini Maria Vittoria, Proto Claudia, Lo Russo Giuseppe, Prelaj Arsela, Segale Miriam, Zanghì Anna, Galli Francesca, Greco Francesca G, Signorelli Diego, Brambilla Marta, Occhipinti Mario, De Braud Filippo, Garassino Marina C, Sozzi Gabriella, Rulli Eliana, Boeri Mattia

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Despite the significant improvement in outcomes for patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs), resistance, whether primary or secondary, remains a substantial challenge. Currently, reliable biomarkers to monitor ICI response are lacking, highlighting the need for minimally invasive tools like liquid biopsy to track treatment efficacy. This study aimed to identify circulating microRNAs (miRNAs) as potential biomarkers to track ICI response in patients with NSCLC.

MATERIALS AND

METHODS

The Apollo longitudinal study enrolled patients with advanced NSCLC receiving ICI in first or subsequent lines. Plasma samples were collected at baseline and follow-up to prospectively assess miRNA profiles until progressive disease (PD). Using a custom reverse transcription-quantitative polymerase chain reaction platform, 276 ratios among 24 lung cancer-related miRNAs were analyzed. The generalized estimating equation and joint models were applied to select the miRNA ratios most associated with PD over time. To control for multiple testing, the Benjamini-Yekutieli method was applied setting a 10% false discovery rate threshold.

RESULTS

From the 211 patients, a total of 454 plasma samples were analyzed. Clinical and biochemical variables had little effect on miRNAs' profile. The analysis identified nine miRNA ratios, all involving miR-145-5p, as significant biomarkers for monitoring treatment response, even after adjustment for the line of therapy. These ratios exhibited a longitudinal modulation pattern consistent with radiologic response, particularly in patients who initially benefited from ICI treatment. In addition, in an independent set of 32 plasma samples from 10 patients receiving ICI as maintenance therapy, the same trends were observed.

CONCLUSION

A focused panel of miRNA ratios, driven by miR-145-5p, effectively reflects response to ICI therapy in patients with advanced NSCLC, highlighting their potential as biomarkers for treatment monitoring.

Для цитирования: Chiaruttini Maria Vittoria, Proto Claudia, Lo Russo Giuseppe, Prelaj Arsela, Segale Miriam, Zanghì Anna, Galli Francesca, Greco Francesca G, Signorelli Diego, Brambilla Marta, Occhipinti Mario, De Braud Filippo, Garassino Marina C, Sozzi Gabriella, Rulli Eliana, Boeri Mattia. Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non-Small Cell Lung Cancer.. JCO precision oncology. 2025. DOI: 10.1200/po-24-00790.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.